HD-OPM Archive
Topics › Lp(a)

Steven Nissen discusses Lp(a)HORIZON results in an AHA 2026 late-breaker interview

Louis Nervegna · Nov 08, 2026 · ♥ 4 reactions · 2 comments · original Facebook post
Lp(a)PCSK9, ezetimibe & newer drugs
AI summary & key facts

Louis shares a Radcliffe Cardiology interview in which Steven Nissen, the trial's principal investigator, and Harriette Van Spall discuss the primary and extended outcome results of Lp(a)HORIZON. The post describes the trial design but no results.

Interview with Dr. Steven Nissan, principle investigator on the Lp(a) HORIZON trial.

Link to full interview:

radcliffeckm.comAha lpahorizon does lowering lpa reduce cv riskradcliffeckm.com

Quoted from the original post:

Lp(a)HORIZON reports new phase 3 data on Lp(a) lowering and cardiovascular outcomes. Dr Steven Nissen and Dr Harriette Van Spall take a closer look at the primary results and extended cardiovascular outcomes analyses from Lp(a)HORIZON in this AHA 2026 Late-Breaker Trial Discussion.

The randomised, double-blind, placebo-controlled trial enrolled 8,323 patients with established cardiovascular disease and elevated lipoprotein(a). It evaluated an Lp(a)-lowering strategy against placebo, assessing major cardiovascular events including cardiovascular death, myocardial infarction, stroke and urgent coronary revascularisation.

Hear their perspectives on the findings and what Lp(a)HORIZON adds to the evidence around targeting elevated Lp(a) in established cardiovascular disease.

Watch the full interview here 🔗Aha lpahorizon does lowering lpa reduce cv risk (radcliffeckm.com)

This is an independent interview produced by Radcliffe Cardiology.

#lpaHD #horizonHD #stevennissanHD #pelacarsenHD

Research cited

← newer: Pelacarsen and ziltivekimab lowered their targets but not evolder: A rising calcium score on a statin does not mean it failed, →